Clinical Trials Logo

Amyotrophic Lateral Sclerosis clinical trials

View clinical trials related to Amyotrophic Lateral Sclerosis.

Filter by:

NCT ID: NCT05176093 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

REViVALS-1B
Start date: November 14, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of intramuscular (IM) administration of Engensis in Participants with Amyotrophic Lateral Sclerosis (ALS) who were previously randomized, received treatment, and completed the Day 180 Visit of Study VMALS-002-2. Safety will be assessed by incidences of treatment-emergent adverse events (TEAEs), treatment emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and the clinically significant laboratory values. See the table below for additional, exploratory endpoints.

NCT ID: NCT05136885 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

Start date: February 21, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.

NCT ID: NCT05039268 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Start date: November 25, 2021
Phase: Phase 2
Study type: Interventional

Phase 2 open label trial to investigate the safety and potentially efficacy of 3K3A-APC in patients with Amyotrophic Lateral Sclerosis (ALS).

NCT ID: NCT05019014 Completed - Alzheimer Disease Clinical Trials

Olfactory Deficits in Neurologic Disease

Start date: August 10, 2011
Phase:
Study type: Observational

The goal of this study is to examine olfactory function in preclinical subjects or individuals with neurological diseases such as Probable Alzheimer's Disease (PRAD), Frontotemporal Dementias (FTD), Dementia with Lewy Bodies (DLB), Traumatic Brain Injury (TBI), and Amyotrophic Lateral Sclerosis (ALS).

NCT ID: NCT05003167 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

A tele-health treatment study for individuals with early stage ALS with the aim to improve communication, cough response, and respiratory strength. All participants complete a respiratory strength training program using an Expiratory Muscle Strength Training (EMST 150) device from the comfort of their homes for 6 weeks.

NCT ID: NCT04953286 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis

LARMOMIQUE
Start date: September 17, 2021
Phase: N/A
Study type: Interventional

Amyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting the motor neuron. Currently, there is no diagnostic test and no examination that can predict the evolution of this pathology. The search for diagnostic and prognostic biomarkers is therefore essential for a better understanding of the pathophysiology of ALS, which remains poorly understood, and also for better clinical management. The ocular surface, made up of liquid elements, tears, and cells, is an accessible anatomical-physiological entity that has demonstrated its usefulness in the identification of biomarkers in neurodegenerative diseases such as Parkinson's or Alzheimer's. To date, no study has explored the ocular surface as a biomarker in ALS

NCT ID: NCT04952025 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Quantitative Analysis of Precise Brain Volume in Amyotrophic Lateral Sclerosis

Start date: January 1, 2015
Phase:
Study type: Observational

Using the original MRI images of 16 ALS patients and 16 normal controls matched by gender, age and education level in the previous study, the differences of brain volume in different parts of ALS patients and normal controls, and the correlation between brain structure and clinical characteristics were compared by precise brain volume quantitative analysis technology.

NCT ID: NCT04950231 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Investigation on Home Care Needs of ALS Patients and Their Caregivers

Start date: September 1, 2020
Phase:
Study type: Observational

The research target 1. To investigate the home nursing knowledge needs of ALS patients; 2. Investigate the needs of ALS caregivers for home nursing knowledge; 3. To compare the differences between patients and caregivers in the knowledge needs of patients' refusal to care, so as to provide patients and caregivers with targeted care, meet the needs of patients, improve the quality of life of patients, and extend the survival period.

NCT ID: NCT04948346 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral Sclerosis

Start date: January 31, 2018
Phase:
Study type: Observational

To verify the correlation between TMAO level and the pathogenesis and progression of ALS

NCT ID: NCT04947436 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

ALS and Airway Clearance (ALSAC) Therapy

ALSAC
Start date: January 25, 2012
Phase: N/A
Study type: Interventional

Patients will receive one of three respiratory therapy interventions for airway clearance assistance: 1) High frequency chest wall oscillation (HFCWO) and mechanical insufflation/exsufflation (MIE), 2) HFCWO or 3) MIE. The study period will be six months and include three clinic visits, baseline and follow-up visits at 3 and 6 months, and 6 monthly home visits by the respiratory therapist.